Literature DB >> 12590650

Purification and identification of a binding protein for pancreatic secretory trypsin inhibitor: a novel role of the inhibitor as an anti-granzyme A.

Satoshi Tsuzuki1, Yoshimasa Kokado, Shigeki Satomi, Yoshie Yamasaki, Hirofumi Hirayasu, Toshihiko Iwanaga, Tohru Fushiki.   

Abstract

Pancreatic secretory trypsin inhibitor (PSTI) is a potent trypsin inhibitor that is mainly found in pancreatic juice. PSTI has been shown to bind specifically to a protein, distinct from trypsin, on the surface of dispersed cells obtained from tissues such as small intestine. In the present study, we affinity-purified the binding protein from the 2% (w/v) Triton X-100-soluble fraction of dispersed rat small-intestinal cells using recombinant rat PSTI. Partial N-terminal sequencing of the purified protein gave a sequence that was identical with the sequence of mouse granzyme A (GzmA), a tryptase produced in cytotoxic lymphocytes. We confirmed the formation of an affinity-cross-linked complex between (125)I-labelled PSTI and recombinant rat GzmA (rGzmA). In situ hybridization and immunostaining revealed the existence of GzmA-expressing intraepithelial lymphocytes in the rat small intestine. We concluded that the PSTI-binding protein isolated from the dispersed cells is GzmA that is produced in the lymphocytes of the tissue. The rGzmA hydrolysed the N -alpha-benzyloxycarbonyl-L-lysine thiobenzyl ester (BLT), and the BLT hydrolysis was inhibited by PSTI. Sulphated glycosaminoglycans, such as fucoidan or heparin, showed almost no effect on the inhibition of rGzmA by PSTI, whereas they decreased the inhibition by antithrombin III. In the present paper, we propose a novel role of PSTI as a GzmA inhibitor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12590650      PMCID: PMC1223377          DOI: 10.1042/BJ20021891

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  28 in total

1.  Extracellular granzyme A, complexed to proteoglycans, is protected against inactivation by protease inhibitors.

Authors:  E H Spaeny-Dekking; A M Kamp; C J Froelich; C E Hack
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

2.  Human pancreatic secretory trypsin inhibitor.

Authors:  L J Greene; M H Pubols; D C Bartelt
Journal:  Methods Enzymol       Date:  1976       Impact factor: 1.600

Review 3.  Granzymes (lymphocyte serine proteases): characterization with natural and synthetic substrates and inhibitors.

Authors:  C M Kam; D Hudig; J C Powers
Journal:  Biochim Biophys Acta       Date:  2000-03-07

4.  Postoperative elevation of serum pancreatic secretory trypsin inhibitor.

Authors:  K Matsuda; M Ogawa; T Shibata; S Nishibe; K Miyauchi; Y Matsuda; T Mori
Journal:  Am J Gastroenterol       Date:  1985-09       Impact factor: 10.864

5.  [On protease inhibitors, V. On the chemistry and physiology of the specific trypsin inhibitors from the ox, dog, pig and human pancreas].

Authors:  H Fritz; I Hüller; M Wiedemann; E Werle
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1967-04

6.  Sensitive substrates for human leukocyte and porcine pancreatic elastase: a study of the merits of various chromophoric and fluorogenic leaving groups in assays for serine proteases.

Authors:  M J Castillo; K Nakajima; M Zimmerman; J C Powers
Journal:  Anal Biochem       Date:  1979-10-15       Impact factor: 3.365

7.  The graphical determination of K m and K i .

Authors:  M Dixon
Journal:  Biochem J       Date:  1972-08       Impact factor: 3.857

8.  Distribution of pancreatic secretory trypsin inhibitor in various human tissues and its inactivation in the gastric mucosa.

Authors:  T Shibata; M Ogawa; N Takata; K Matsuda; T Niinobu; K Uda; C Wakasugi; T Mori
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1987-02

9.  Extracellular granzymes A and B in humans: detection of native species during CTL responses in vitro and in vivo.

Authors:  E H Spaeny-Dekking; W L Hanna; A M Wolbink; P C Wever; J A Kummer; A J Kummer; A J Swaak; J M Middeldorp; H G Huisman; C J Froelich; C E Hack
Journal:  J Immunol       Date:  1998-04-01       Impact factor: 5.422

10.  Radioimmunoassay for human pancreatic secretory trypsin inhibitor: measurement of serum pancreatic secretory trypsin inhibitor in normal subjects and subjects with pancreatic diseases.

Authors:  T Kitahara; Y Takatsuka; K I Fujimoto; S Tanaka; M Ogawa; G Kosaki
Journal:  Clin Chim Acta       Date:  1980-04-25       Impact factor: 3.786

View more
  13 in total

Review 1.  Granzyme A activates another way to die.

Authors:  Judy Lieberman
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

Review 2.  Death by a thousand cuts: granzyme pathways of programmed cell death.

Authors:  Dipanjan Chowdhury; Judy Lieberman
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

3.  Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis.

Authors:  Jason Lamontagne; Mark Pinkerton; Timothy M Block; Xuanyong Lu
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

4.  Identification of Serpinb6b as a species-specific mouse granzyme A inhibitor suggests functional divergence between human and mouse granzyme A.

Authors:  Dion Kaiserman; Sarah E Stewart; Kim Plasman; Kris Gevaert; Petra Van Damme; Phillip I Bird
Journal:  J Biol Chem       Date:  2014-02-06       Impact factor: 5.157

5.  Identification of the matriptase second CUB domain as the secondary site for interaction with hepatocyte growth factor activator inhibitor type-1.

Authors:  Kuniyo Inouye; Satoshi Tsuzuki; Makoto Yasumoto; Kenji Kojima; Seiya Mochida; Tohru Fushiki
Journal:  J Biol Chem       Date:  2010-08-03       Impact factor: 5.157

6.  Granzyme A and thrombin differentially promote the release of interleukin-8 from alveolar epithelial A549 cells.

Authors:  Yumiko Yoshikawa; Hirofumi Hirayasu; Satoshi Tsuzuki; Tohru Fushiki
Journal:  Cytotechnology       Date:  2010-04-28       Impact factor: 2.058

7.  Evidence for the occurrence of membrane-type serine protease 1/matriptase on the basolateral sides of enterocytes.

Authors:  Satoshi Tsuzuki; Nobuhito Murai; Yuka Miyake; Kuniyo Inouye; Hirofumi Hirayasu; Toshihiko Iwanaga; Tohru Fushiki
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

8.  Role of the inflammatory protein serine protease inhibitor Kazal in preventing cytolytic granule granzyme A-mediated apoptosis.

Authors:  Felix Lu; Jason Lamontagne; Angela Sun; Mark Pinkerton; Timothy Block; Xuanyong Lu
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

9.  A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis.

Authors:  Kristina K Hansen; Philip M Sherman; Laurie Cellars; Patricia Andrade-Gordon; Zhengying Pan; Amos Baruch; John L Wallace; Morley D Hollenberg; Nathalie Vergnolle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-26       Impact factor: 11.205

10.  Involvement of the cytoplasmic juxtamembrane region of matriptase in its exclusive localization to the basolateral membrane domain of Madin-Darby canine kidney epithelial cells.

Authors:  Nobuhito Murai; Yuka Miyake; Satoshi Tsuzuki; Kuniyo Inouye; Tohru Fushiki
Journal:  Cytotechnology       Date:  2009-06-26       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.